1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Competitor Analysis: Dengue Virus Vaccines and Therapeutics

Competitor Analysis: Dengue Virus Vaccines and Therapeutics

  • July 2012
  • -
  • La Merie Publishing
  • -
  • 27 pages

The present Competitive Intelligence Report about Dengue Virus Vaccines & Therapeutics provides a competitor evaluation in the field of investigational vaccines and therapeutics against one or more serotypes of Dengue Virus for prophylaxis or treatment of Dengue fever as of July 2012. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
It is estimated that about 100 million cases of infection by Dengue virus occur each year and that nearly half the world’s population is at risk of Dengue virus infection. At present, no vaccines are available to prevent infection with mosquito-borne Dengue virus. There are four serotypes of Dengue virus, and neutralizing antibodies are serotype-specific with the risk of sequential infections. Although immunity against a specific serotype is life-long, but previous infection with one serotype is a risk factor for a more severe form of Dengue (Dengue hemorrhagic fever) upon subsequent infection with another serotype, thus emphasizing the need for a tetravalent vaccine against all four serotpyes of Dengue virus.
The report includes a compilation of currently active projects in research and development of vaccines targeting Dengue virus for prophylaxis of Dengue fever and of therapeutics for treatment of Dengue fever. In addition, the report lists company-specific R&D pipelines of Dengue Virus Vaccines & Therapeutics. Competitor projects are listed in a tabular format providing information on:
• Drug Codes,
• Target / Mechanism of Action,
• Class of Compound,
• Company,
• Product Category,
• Indication,
• R&D Stage and
• additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table Of Contents

Competitor Analysis: Dengue Virus Vaccines and Therapeutics
Competitor Analysis: Dengue Virus Vaccines and Therapeutics

Index

Dengue Virus Vaccines
Dengue Virus Vaccines from NIH / NIAID
Dengue Virus Vaccines Licensed from NIH to Manufacturers in Developing Countries
Dengue Virus Therapeutics
CorporateDengue Virus Vaccines and Therapeutics RandD Pipeline
About La Merie

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
OpportunityAnalyzer: Idiopathic Pulmonary Fibrosis - Opportunity Analysis and Forecast to 2025

OpportunityAnalyzer: Idiopathic Pulmonary Fibrosis - Opportunity Analysis and Forecast to 2025

  • $ 9 495
  • Industry report
  • June 2016
  • by Global Data

OpportunityAnalyzer: Idiopathic Pulmonary Fibrosis - Opportunity Analysis and Forecast to 2025 Summary The IPF therapeutic market is currently dominated by the only two drugs that have gained marketing ...

Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Frontier Pharma: Diabetic Complications - Innovative and Diverse Neuropathies, Nephropathy and Retinopathies Pipelines Demonstrate Shift Towards Disease Modifying Therapies

Frontier Pharma: Diabetic Complications - Innovative and Diverse Neuropathies, Nephropathy and Retinopathies Pipelines Demonstrate Shift Towards Disease Modifying Therapies

  • $ 6 995
  • Industry report
  • June 2016
  • by GBI Research

Frontier Pharma: Diabetic Complications - Innovative and Diverse Neuropathies, Nephropathy and Retinopathies Pipelines Demonstrate Shift Towards Disease Modifying Therapies Summary Diabetes is a common ...


Download Unlimited Documents from Trusted Public Sources

Anti-Infective Market in the UK

  • September 2016
    19 pages
  • Anti-Infective  

  • United Kingdom  

    Europe  

View report >

Therapy Market in Sweden

  • September 2016
    8 pages
  • Therapy  

    Hormone  

    Antidiabetics  

  • Sweden  

View report >

Opioid and Therapy Market in the US

  • September 2016
    11 pages
  • Opioid  

    Therapy  

    Analgesic  

  • United States  

View report >

Related Market Segments :

Therapy
Vaccine
Dengue Virus Vaccine

ref:plp2012

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.